293 results on '"Nielsen LB"'
Search Results
2. P660Molecular insight in apoM-S1P-induced cardioprotection against ischemia/reperfusion injury
- Author
-
Morel, S., Christoffersen, C., Rochemont, V., Montecucco, F., Frias, M., Pelli, G., Mach, F., James, RW, Nielsen, LB, Kwak, BR, Morel, S., Christoffersen, C., Rochemont, V., Montecucco, F., Frias, M., Pelli, G., Mach, F., James, RW, Nielsen, LB, and Kwak, BR
- Abstract
Purpose: Apolipoprotein M (apoM) is a plasma lipoprotein that mainly associates with high-density lipoproteins (HDL) and that serves as a carrier of the bioactive lipid Sphingosine-1-Phosphate (S1P). Recent studies indicate that S1P binding to G-protein-coupled receptors, known as S1P-receptors, in the heart activates signalling pathways promoting cardiomyocyte survival, but downstream targets are largely unknown. Here, we investigate the putative role of the apoM-S1P axis in relation to cardioprotection against ischemia/reperfusion (IR) injury. Methods and Results: ApoM transgenic (Apom-Tg) mice, in which plasma S1P is increased by >250%, and wild-type (WT) mice were subjected to 30 min of left coronary artery ligation and 24 hrs reperfusion in vivo. We found a reduction of infarct size in Apom-Tg mice (15±1%) in comparison with WT mice (29±4%, N=8-9, p<0.01). In agreement, neutrophil infiltration into the infarcted area was lower in Apom-Tg mice (14.8±0.2% vs. 25.9±5.1 in WT, N=3, p<0.05). Interestingly, 5 min of S1P treatment at the onset of reperfusion reduced infarct size in response to 30 min of no-flow global ischemia (control: 23±3%, S1P-treated: 11±2%, N=5, p<0.05) in ex vivo Langendorff perfused hearts, suggesting that S1P exerts a direct protective effect on cardiomyocytes. Moreover, the sensitivity to ex vivo IR of Apom-Tg mice was not different from WT mice, further supporting that the cardioprotective effect observed in vivo is due to increased plasmatic S1P in these mice. To obtain further insight into the mechanism underlying S1P-induced cardioprotection, neonatal rat ventricular cardiomyocytes were treated for 5 min with S1P after pre-incubation with PKC kinase inhibitors or with specific antagonists of S1P receptors. We found by Western blot that S1P induced phosphorylation of the gap junction protein Connexin43 (Cx43) on Serine 368 by a PKC-dependent mechanism and that this phosphorylation was mediated by S1P2 and S1P3 but not by S1P1 receptors. F
- Published
- 2017
3. Acute hypoxemic respiratory failure in immunocompromised patients: the Efraim multinational prospective cohort study.
- Author
-
Azoulay, E, Pickkers, P, Soares, M, Perner, A, Rello, J, Bauer, Pr, van de Louw, A, Hemelaar, P, Lemiale, V, Taccone, F, Martin Loeches, I, Meyhoff, T, Salluh, J, Schellongowski, P, Rusinova, K, Terzi, N, Mehta, S, Antonelli, Massimo, Kouatchet, A, Barratt-Due, A, Valkonen, M, Landburg, Pp, Bruneel, F, Bukan, Rb, Pène, F, Metaxa, V, Moreau, A, Souppart, V, Burghi, G, Girault, C, Silva, Uva, Montini, Luca, Barbier, F, Nielsen, Lb, Gaborit, B, Mokart, D, Chevret, S, Efraim investigators and the Nine-I study, Group, Antonelli M (ORCID:0000-0003-3007-1670), Montini L (ORCID:0000-0003-4602-5134), Azoulay, E, Pickkers, P, Soares, M, Perner, A, Rello, J, Bauer, Pr, van de Louw, A, Hemelaar, P, Lemiale, V, Taccone, F, Martin Loeches, I, Meyhoff, T, Salluh, J, Schellongowski, P, Rusinova, K, Terzi, N, Mehta, S, Antonelli, Massimo, Kouatchet, A, Barratt-Due, A, Valkonen, M, Landburg, Pp, Bruneel, F, Bukan, Rb, Pène, F, Metaxa, V, Moreau, A, Souppart, V, Burghi, G, Girault, C, Silva, Uva, Montini, Luca, Barbier, F, Nielsen, Lb, Gaborit, B, Mokart, D, Chevret, S, Efraim investigators and the Nine-I study, Group, Antonelli M (ORCID:0000-0003-3007-1670), and Montini L (ORCID:0000-0003-4602-5134)
- Abstract
BACKGROUND: In immunocompromised patients with acute hypoxemic respiratory failure (ARF), initial management aims primarily to avoid invasive mechanical ventilation (IMV). METHODS: To assess the impact of initial management on IMV and mortality rates, we performed a multinational observational prospective cohort study in 16 countries (68 centers). RESULTS: A total of 1611 patients were enrolled (hematological malignancies 51.9%, solid tumors 35.2%, systemic diseases 17.3%, and solid organ transplantation 8.8%). The main ARF etiologies were bacterial (29.5%), viral (15.4%), and fungal infections (14.7%), or undetermined (13.2%). On admission, 915 (56.8%) patients were not intubated. They received standard oxygen (N = 496, 53.9%), high-flow oxygen (HFNC, N = 187, 20.3%), noninvasive ventilation (NIV, N = 153, 17.2%), and NIV + HFNC (N = 79, 8.6%). Factors associated with IMV included age (hazard ratio = 0.92/year, 95% CI 0.86-0.99), day-1 SOFA (1.09/point, 1.06-1.13), day-1 PaO2/FiO2 (1.47, 1.05-2.07), ARF etiology (Pneumocystis jirovecii pneumonia (2.11, 1.42-3.14), invasive pulmonary aspergillosis (1.85, 1.21-2.85), and undetermined cause (1.46, 1.09-1.98). After propensity score matching, HFNC, but not NIV, had an effect on IMV rate (HR = 0.77, 95% CI 0.59-1.00, p = 0.05). ICU, hospital, and day-90 mortality rates were 32.4, 44.1, and 56.4%, respectively. Factors independently associated with hospital mortality included age (odds ratio = 1.18/year, 1.09-1.27), direct admission to the ICU (0.69, 0.54-0.87), day-1 SOFA excluding respiratory score (1.12/point, 1.08-1.16), PaO2/FiO2 < 100 (1.60, 1.03-2.48), and undetermined ARF etiology (1.43, 1.04-1.97). Initial oxygenation strategy did not affect mortality; however, IMV was associated with mortality, the odds ratio depending on IMV conditions: NIV + HFNC failure (2.31, 1.09-4.91), first-line IMV (2.55, 1.94-3.29), NIV failure (3.65, 2.05-6.53), standard oxygen failure (4.16, 2.91-5.93), and HFNC failure (5.54, 3.27-9
- Published
- 2017
4. Amplification for Listeners with Steeply Sloping, High-Frequency Hearing Loss
- Author
-
Nielsen Lb, Allsman Cs, Jean A. Sullivan, and Mobley Jp
- Subjects
Male ,Frequency response ,medicine.medical_specialty ,Hearing loss ,Intelligibility (communication) ,Audiology ,Models, Biological ,Speech and Hearing ,Hearing Aids ,otorhinolaryngologic diseases ,medicine ,Humans ,Cutoff ,Hearing Loss, Central ,Phonation ,Hearing Disorders ,Aged ,Mathematics ,High frequency hearing loss ,Amplifiers, Electronic ,Speech Intelligibility ,Auditory Threshold ,Equipment Design ,Middle Aged ,Speech Articulation Tests ,Cutoff frequency ,Otorhinolaryngology ,QUIET ,Speech Perception ,medicine.symptom - Abstract
Two experiments were conducted to determine the effects of various upper cutoff frequencies on performance of listeners with steeply sloping, high-frequency hearing loss. The upper cutoff frequency of individually prescribed responses was systematically adjusted to 0.71, 1.79, and 6.0 kHz. Measures of nonsense syllable recognition and subjective ratings of speech intelligibility and speech quality were obtained at three overall gain settings for each frequency response. Experiment 1 assessed performance on tests in quiet and Experiment 2 assessed performance on tests in noise. Nonsense syllable recognition improved as the upper cutoff frequency increased, particularly for tests in noise. In contrast, the subjects gave significantly poorer quality ratings for the shaped response with the highest cutoff frequency (6.0 kHz). Few significant effects of cutoff frequency were found for ratings of intelligibility in either quiet or noise.
- Published
- 1992
- Full Text
- View/download PDF
5. Impact of IDDM2 on disease pathogenesis and progression in children with newly diagnosed type 1 diabetes: reduced insulin antibody titres and preserved beta cell function
- Author
-
Nielsen, LB, Chiarelli, F, Holl, R, Swift, P, de Beaufort, C, Pociot, F, Hougaard, Philip, Gammeltoft, S, Knip, M, and Hansen, L
- Abstract
Udgivelsesdato: Januar
- Published
- 2006
6. Glycaemic threshold for diabetes-specific retinopathy among individuals from Saudi Arabia, Algeria and Portugal.
- Author
-
Almdal, Thomas Peter, Handlos, Line Neerup, Vistisen, Dorte, Valerius, M, Juul, E, Nielsen, KE, Nielsen, LB, Sheikh, A, Belhadj, M, Nadir, D, Zinai, S, Raposo, J, Lund-Andersen, Henrik, Witte, Daniel Rinse, Almdal, Thomas Peter, Handlos, Line Neerup, Vistisen, Dorte, Valerius, M, Juul, E, Nielsen, KE, Nielsen, LB, Sheikh, A, Belhadj, M, Nadir, D, Zinai, S, Raposo, J, Lund-Andersen, Henrik, and Witte, Daniel Rinse
- Abstract
We studied the glycaemic threshold and prevalence of diabetic retinopathy in screen-detected diabetes in Saudi Arabia, Algeria and Portugal. The prevalence of diabetes-specific retinopathy started to increase at an HbA1c level of 6-6.4% and in individuals with HbA1c >7.0% the prevalence was 6.0%.
- Published
- 2014
7. The microsomal triglyceride transfer protein gene-493T variant lowers cholesterol but increases the risk of coronary heart disease
- Author
-
Ledmyr, H, McMahon, AD, Ehrenborg, E, Nielsen, LB, Neville, M, Lithell, H, MacFarlane, PW, Packard, CJ, Karpe, F, Ledmyr, H, McMahon, AD, Ehrenborg, E, Nielsen, LB, Neville, M, Lithell, H, MacFarlane, PW, Packard, CJ, and Karpe, F
- Published
- 2004
8. Abstract: P419 RELATIONSHIP BETWEEN PLASMA APOLIPOPROTEIN-M AND HIGH DENSITY LIPOPROTEIN APOA KINETICS IN MEN
- Author
-
Ooi, E, primary, Watts, G, additional, Chan, D, additional, Nielsen, LB, additional, Plomgaard, P, additional, Dahlback, B, additional, and Barrett, H, additional
- Published
- 2009
- Full Text
- View/download PDF
9. Apoteksfarmaceutens tavshedspligt - et etisk dilemma?
- Author
-
Nielsen, CB, Nielsen, LB, Nielsen, M, Nørgaard, Lotte Stig, Nieman, Mie Riise, Ridderberg, Signe, Ørting, M, Nielsen, CB, Nielsen, LB, Nielsen, M, Nørgaard, Lotte Stig, Nieman, Mie Riise, Ridderberg, Signe, and Ørting, M
- Published
- 1997
10. Hormonal treatment of cryptorchidism—hCG or GnRH—a multicentre study
- Author
-
Christiansen, P, primary, Müller, J, additional, Buhl, S, additional, Hansen, OR, additional, Hobolth, N, additional, Jacobsen, BB, additional, Jørgensen, PH, additional, Kastrup, KW, additional, Nielsen, K, additional, Nielsen, LB, additional, Pedersen-Bjergaard, L, additional, Petersen, KE, additional, Petersen, SA, additional, Thamdrup, E, additional, Thisted, E, additional, Tranebjærg, L, additional, and Skakkebæk, NE, additional
- Published
- 1992
- Full Text
- View/download PDF
11. Apolipoprotein M predicts pre-beta-HDL formation: studies in type 2 diabetic and nondiabetic subjects.
- Author
-
Plomgaard P, Dullaart RP, de Vries R, Groen AK, Dahlbäck B, and Nielsen LB
- Abstract
OBJECTIVE: Studies in mice suggest that plasma apoM is lowered in hyperinsulinaemic diabetes and that apoM stimulates formation of pre-beta-HDL. Pre-beta-HDL is an acceptor of cellular cholesterol and may be critical for reverse cholesterol transport. Herein, we examined whether patients with type 2 diabetes have reduced plasma apoM and whether apoM is associated with pre-beta-HDL formation and cellular cholesterol efflux. DESIGN: In 78 patients with type 2 diabetes and 89 control subjects, we measured plasma apoM with ELISA, pre-beta-HDL and pre-beta-HDL formation, phospholipid transfer protein (PLTP) activity and the ability of plasma to promote cholesterol efflux from cultured fibroblasts. RESULTS: ApoM was approximately 9% lower in patients with type 2 diabetes compared to controls (0.025 +/- 0.006 vs. 0.027 +/- 0.007 g L(-1), P = 0.01). The difference in apoM was largely attributable to diabetes-associated obesity. ApoM was positively related to both HDL (r = 0.16; P = 0.04) and LDL cholesterol (r = 0.28; P = 0.0003). Pre-beta-HDL and pre-beta-HDL formation were not different between diabetic and control subjects. ApoM predicted pre-beta-HDL (r = 0.16; P = 0.04) and pre-beta-HDL formation (r = 0.19; P = 0.02), even independently of positive relationships with apoA-I, HDL-cholesterol and PLTP activity. Cellular cholesterol efflux to plasma was positively related to pre-beta-HDL and PLTP activity but not significantly to apoM. CONCLUSIONS: Plasma apoM is modestly reduced in type 2 diabetes. Pre-beta-HDL and pre-beta-HDL formation are positively associated with apoM, supporting the hypothesis that apoM plays a role in HDL remodelling in humans. Lower apoM may provide a mechanism to explain why pre-beta-HDL formation is not increased in type 2 diabetes despite elevated PLTP activity. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
12. Progestins oppose the effects of estradiol on the endothelin-1 receptor type B in coronary arteries from ovariectomized hyperlipidemic rabbits.
- Author
-
Pedersen SH, Nielsen LB, Mortensen A, Nilas L, and Ottesen B
- Published
- 2008
- Full Text
- View/download PDF
13. Interceptive treatment of Class II, Division 2.
- Author
-
Litt, Richard A. and Nielsen, lb Leth
- Published
- 1984
14. P660Molecular insight in apoM-S1P-induced cardioprotection against ischemia/reperfusion injury
- Author
-
Morel, S., Christoffersen, C., Rochemont, V., Montecucco, F., Frias, M., Pelli, G., Mach, F., James, RW, Nielsen, LB, Kwak, BR, Morel, S., Christoffersen, C., Rochemont, V., Montecucco, F., Frias, M., Pelli, G., Mach, F., James, RW, Nielsen, LB, and Kwak, BR
- Abstract
Purpose: Apolipoprotein M (apoM) is a plasma lipoprotein that mainly associates with high-density lipoproteins (HDL) and that serves as a carrier of the bioactive lipid Sphingosine-1-Phosphate (S1P). Recent studies indicate that S1P binding to G-protein-coupled receptors, known as S1P-receptors, in the heart activates signalling pathways promoting cardiomyocyte survival, but downstream targets are largely unknown. Here, we investigate the putative role of the apoM-S1P axis in relation to cardioprotection against ischemia/reperfusion (IR) injury. Methods and Results: ApoM transgenic (Apom-Tg) mice, in which plasma S1P is increased by >250%, and wild-type (WT) mice were subjected to 30 min of left coronary artery ligation and 24 hrs reperfusion in vivo. We found a reduction of infarct size in Apom-Tg mice (15±1%) in comparison with WT mice (29±4%, N=8-9, p<0.01). In agreement, neutrophil infiltration into the infarcted area was lower in Apom-Tg mice (14.8±0.2% vs. 25.9±5.1 in WT, N=3, p<0.05). Interestingly, 5 min of S1P treatment at the onset of reperfusion reduced infarct size in response to 30 min of no-flow global ischemia (control: 23±3%, S1P-treated: 11±2%, N=5, p<0.05) in ex vivo Langendorff perfused hearts, suggesting that S1P exerts a direct protective effect on cardiomyocytes. Moreover, the sensitivity to ex vivo IR of Apom-Tg mice was not different from WT mice, further supporting that the cardioprotective effect observed in vivo is due to increased plasmatic S1P in these mice. To obtain further insight into the mechanism underlying S1P-induced cardioprotection, neonatal rat ventricular cardiomyocytes were treated for 5 min with S1P after pre-incubation with PKC kinase inhibitors or with specific antagonists of S1P receptors. We found by Western blot that S1P induced phosphorylation of the gap junction protein Connexin43 (Cx43) on Serine 368 by a PKC-dependent mechanism and that this phosphorylation was mediated by S1P2 and S1P3 but not by S1P1 receptors. F
15. Computerised tomography after posterior dislocation of the hip
- Author
-
Hougaard, K, primary, Lindequist, S, additional, and Nielsen, LB, additional
- Published
- 1987
- Full Text
- View/download PDF
16. P660 Molecular insight in apoM-S1P-induced cardioprotection against ischemia/reperfusion injury.
- Author
-
Morel, S, Christoffersen, C, Rochemont, V, Montecucco, F, Frias, M, Pelli, G, Mach, F, James, RW, Nielsen, LB, and Kwak, BR
- Subjects
MOLECULAR structure ,ISCHEMIA ,REPERFUSION injury ,APOLIPOPROTEINS ,LABORATORY mice ,BLOOD plasma - Abstract
Purpose: Apolipoprotein M (apoM) is a plasma lipoprotein that mainly associates with high-density lipoproteins (HDL) and that serves as a carrier of the bioactive lipid Sphingosine-1-Phosphate (S1P). Recent studies indicate that S1P binding to G-protein-coupled receptors, known as S1P-receptors, in the heart activates signalling pathways promoting cardiomyocyte survival, but downstream targets are largely unknown. Here, we investigate the putative role of the apoM-S1P axis in relation to cardioprotection against ischemia/reperfusion (IR) injury.Methods and Results: ApoM transgenic (Apom-Tg) mice, in which plasma S1P is increased by >250%, and wild-type (WT) mice were subjected to 30 min of left coronary artery ligation and 24 hrs reperfusion in vivo. We found a reduction of infarct size in Apom-Tg mice (15±1%) in comparison with WT mice (29±4%, N=8-9, p<0.01). In agreement, neutrophil infiltration into the infarcted area was lower in Apom-Tg mice (14.8±0.2% vs. 25.9±5.1 in WT, N=3, p<0.05). Interestingly, 5 min of S1P treatment at the onset of reperfusion reduced infarct size in response to 30 min of no-flow global ischemia (control: 23±3%, S1P-treated: 11±2%, N=5, p<0.05) in ex vivo Langendorff perfused hearts, suggesting that S1P exerts a direct protective effect on cardiomyocytes. Moreover, the sensitivity to ex vivo IR of Apom-Tg mice was not different from WT mice, further supporting that the cardioprotective effect observed in vivo is due to increased plasmatic S1P in these mice. To obtain further insight into the mechanism underlying S1P-induced cardioprotection, neonatal rat ventricular cardiomyocytes were treated for 5 min with S1P after pre-incubation with PKC kinase inhibitors or with specific antagonists of S1P receptors. We found by Western blot that S1P induced phosphorylation of the gap junction protein Connexin43 (Cx43) on Serine 368 by a PKC-dependent mechanism and that this phosphorylation was mediated by S1P2 and S1P3 but not by S1P1 receptors. Finally, 5 min of S1P treatment reduced gap junctional communication between cardiomyocytes (9±1 cells, N=29) in comparison to control conditions (15±2 cells, N=34, p<0.01), as assessed by dye coupling assay.Conclusion: Increased plasma apoM-S1P in mice protects the heart against IR injury. The molecular mechanism might involve reduced cardiomyocyte death by activation of S1P2 and S1P3 receptors, which leads to PKC-dependent phosphorylation of Cx43 and reduction of cell-to-cell coupling. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
17. ACE inhibition attenuates uremia-induced aortic valve thickening in a novel mouse model.
- Author
-
Simolin MA, Pedersen TX, Bro S, Mäyränpää MI, Helske S, Nielsen LB, Kovanen PT, Simolin, Mikko A, Pedersen, Tanja X, Bro, Susanne, Mäyränpää, Mikko I, Helske, Satu, Nielsen, Lars B, and Kovanen, Petri T
- Abstract
Background: We examined whether impaired renal function causes thickening of the aortic valve leaflets in hyperlipidemic apoE-knockout (apoE-/-) mice, and whether the putative effect on the aortic valves could be prevented by inhibiting the angiotensin-converting enzyme (ACE) with enalapril.Methods: Thickening of the aortic valve leaflets in apoE-/- mice was induced by producing mild or moderate chronic renal failure resulting from unilateral nephrectomy (1/2 NX, n = 18) or subtotal nephrectomy (5/6 NX, n = 22), respectively. Additionally, the 5/6 NX mice were randomized to no treatment (n = 8) or enalapril treatment (n = 13). The maximal thickness of each leaflet was measured from histological sections of the aortic roots.Results: Leaflet thickness was significantly greater in the 5/6 NX mice than in the 1/2 NX mice (P = 0.030) or the unoperated mice (P = 0.003). The 5/6 NX mice treated with enalapril had significantly thinner leaflets than did the untreated 5/6 NX mice (P = 0.014).Conclusion: Moderate uremia causes thickening of the aortic valves in apoE-/- mice, which can be attenuated by ACE inhibition. The nephrectomized apoE-/- mouse constitutes a new model for investigating the mechanisms of uremia-induced aortic valve disease, and also provides an opportunity to study its pharmacologic prevention. [ABSTRACT FROM AUTHOR]- Published
- 2009
- Full Text
- View/download PDF
18. Severely impaired von Willebrand factor-dependent platelet aggregation in patients with a continuous-flow left ventricular assist device (HeartMate II)
- Author
-
Klovaite J, Gustafsson F, Mortensen SA, Sander K, and Nielsen LB
- Published
- 2009
- Full Text
- View/download PDF
19. [Christmas article: collisions between roe deer and ambulances].
- Author
-
Winther M, Sørensen OB, Nielsen LB, Wittrock D, and Mikkelsen S
- Subjects
- Animals, Denmark, Humans, Registries, Holidays, Child, Ambulances statistics & numerical data, Accidents, Traffic statistics & numerical data, Reindeer, Deer
- Abstract
Introduction: Due to the Danish fauna, reindeer are not immediately available should Santa Claus need to replace his reindeer while traveling across Denmark with Christmas gifts. Instead, Santa Claus should rely on roe deer, which are predominant in Denmark. However, the population of roe deer may be threatened by collisions between ambulances and roe deer. We decided to study the extent of the problem., Methods: We conducted a register-based study of all traffic accidents involving animals in the Region of Southern Denmark from 2017 through 2022. All traffic accidents were investigated and the number of roe deer accidents were registered., Results: During six years, 317,288 ambulances were dispatched. A total of 334 traffic accidents were reported. Of these, 32 roe deer accidents., Conclusion: To ensure the children that Santa Claus can replace his reindeer and thus contribute to the children's feelings of safety during Christmas, the emergency medical service in Denmark should consider finding means to reduce the number of collisions between roe deer and ambulances., Funding: None., Trial Registration: None., (Published under Open Access CC-BY-NC-BD 4.0. https://creativecommons.org/licenses/by-nc-nd/4.0/.)
- Published
- 2024
- Full Text
- View/download PDF
20. Platelet transfusions in adult ICU patients with thrombocytopenia: A sub-study of the PLOT-ICU inception cohort study.
- Author
-
Anthon CT, Pène F, Perner A, Azoulay E, Puxty K, Van De Louw A, Chawla S, Castro P, Povoa P, Coelho L, Metaxa V, Kochanek M, Liebregts T, Kander T, Sivula M, Andreasen JB, Nielsen LB, Hvas CL, Dufranc E, Canet E, Wright CJ, Schmidt J, Uhel F, Missri L, Krag M, Cos Badia E, Díaz-Lagares C, Menat S, Voiriot G, Erikstrup Clausen N, Lorentzen K, Kvåle R, Barratt-Due A, Hildebrandt T, Holten AR, Strand K, Bestle MH, Klepstad P, Vimpere D, Paulino C, Lueck C, Juhl CS, Costa C, Bådstøløkken PM, Lêdo LSA, Møller MH, and Russell L
- Subjects
- Humans, Female, Male, Cohort Studies, Middle Aged, Aged, Europe, Adult, Critical Care methods, Platelet Transfusion statistics & numerical data, Thrombocytopenia therapy, Intensive Care Units
- Abstract
Background: Platelet transfusions are frequently used in the intensive care unit (ICU), but current practices including used product types, volumes, doses and effects are unknown., Study Design and Methods: Sub-study of the inception cohort study 'Thrombocytopenia and Platelet Transfusions in the ICU (PLOT-ICU)', including acutely admitted, adult ICU patients with thrombocytopenia (platelet count <150 × 10
9 /L). The primary outcome was the number of patients receiving platelet transfusion in ICU by product type. Secondary outcomes included platelet transfusion details, platelet increments, bleeding, other transfusions and mortality., Results: Amongst 504 patients with thrombocytopenia from 43 hospitals in 10 countries in Europe and the United States, 20.8% received 565 platelet transfusions; 61.0% received pooled products, 21.9% received apheresis products and 17.1% received both with a median of 2 (interquartile range 1-4) days from admission to first transfusion. The median volume per transfusion was 253 mL (180-308 mL) and pooled products accounted for 59.1% of transfusions, however, this varied across countries. Most centres (73.8%) used fixed dosing (medians ranging from 2.0 to 3.5 × 1011 platelets/transfusion) whilst some (mainly in France) used weight-based dosing (ranging from 0.5 to 0.7 × 1011 platelets per 10 kg body weight). The median platelet count increment for a single prophylactic platelet transfusion was 2 (-1 to 8) × 109 /L. Outcomes of patients with thrombocytopenia who did and did not receive platelet transfusions varied., Conclusions: Among acutely admitted, adult ICU patients with thrombocytopenia, 20.8% received platelet transfusions in ICU of whom most received pooled products, but considerable variation was observed in product type, volumes and doses across countries. Prophylactic platelet transfusions were associated with limited increases in platelet counts., (© 2024 The Author(s). Acta Anaesthesiologica Scandinavica published by John Wiley & Sons Ltd on behalf of Acta Anaesthesiologica Scandinavica Foundation.)- Published
- 2024
- Full Text
- View/download PDF
21. Follow-Up Study of Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine Against All-Type and Serotype-Specific Invasive Pneumococcal Disease, Denmark.
- Author
-
Nielsen KF, Nielsen LB, Dalby T, Lomholt FK, Slotved HC, Fuursted K, Harboe ZB, Jørgensen CS, and Valentiner-Branth P
- Subjects
- Humans, Denmark epidemiology, Female, Aged, Male, Follow-Up Studies, Aged, 80 and over, Vaccine Efficacy, Vaccination, Pneumococcal Vaccines immunology, Pneumococcal Vaccines administration & dosage, Pneumococcal Infections prevention & control, Pneumococcal Infections epidemiology, Pneumococcal Infections microbiology, Pneumococcal Infections immunology, Serogroup, Streptococcus pneumoniae immunology, Streptococcus pneumoniae classification
- Abstract
As a follow-up to a previous study, we investigated vaccine effectiveness (VE) of 23-valent pneumococcal polysaccharide vaccine (PPSV23) against invasive pneumococcal disease (IPD) among 1,254,498 persons >65 years of age as part of a vaccination program in Denmark during April 2020-January 2023. We assessed VE by using a Cox regression model and adjusted for age, sex, and underlying conditions. Using nationwide data, we estimated a VE of PPSV23 against all-type IPD of 32% and against PPSV23-serotype IPD of 41%. Because this follow-up study had more statistical power than the original study, we also estimated VE against IPD caused by PPSV23-serotypes excluding serotype 3; serotype 3; serotype 8; serotype 22F; PPSV23 non-PCV15 serotypes; PPSV23 non-PCV20 serotypes; and IPD over time. Our findings suggest PPSV23 vaccination can protect persons >65 years of age against IPD caused by all serotypes or serotype groupings, except serotype 3.
- Published
- 2024
- Full Text
- View/download PDF
22. Risk of pharmacological treatment of anxiety and depression after admission for acute exacerbation of chronic obstructive pulmonary disease.
- Author
-
Hermann Karlsen J, Jacobsen PA, Kragholm K, Torp-Pedersen C, Nielsen LB, and Weinreich UM
- Abstract
Background: Anxiety and depression are very common in patients with COPD and may lead to lower quality of life and higher risk of exacerbations and mortality. This study aimed to examine the incidence of anxiety and depression within one year after admission with acute exacerbation in COPD (AECOPD). The secondary aim was to examine the characteristics of the patients who develop anxiety and depression., Methods: This retrospective cohort study used the Danish National Patient Registry. Patients aged 40-90 years admitted for COPD between 01.01.99 and 31.12.18 were included. Patients with mental disorders within 10 years before admission were excluded. Age, sex, educational level, inhaled medication, and comorbidities were evaluated. Anxiety or depression were defined by redemption of anxiolytics or antidepressants within one year after admission., Results: We included 97,929 patients. Anxiolytics and antidepressants were redeemed by 4 and 5 % of patients respectively. Higher age, male sex, treatment with short acting β2-agonists and short acting muscarinic antagonists, cancer and heart failure were positively associated to risk of anxiety or depression, while diabetes and treatment with triple inhalation therapy showed an inverse association., Conclusion: Respectively four and five per cent of patients redeemed anxiolytics and antidepressants within the first year after their first severe AECOPD. Several patient characteristics were significantly associated to risk of anxiety or depression. The results from this study support that there is a risk of anxiety and depression after AECOPD in addition to the known risk of preexisting anxiety and depression., Competing Interests: Declaration of competing interest The authors declare that they have no conflict of interest to disclose., (Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
23. The association between alcohol consumption and pulmonary function: a scoping review.
- Author
-
Nielsen LB, Johansen MO, Riddersholm SJ, and Weinreich UM
- Subjects
- Humans, Risk Factors, Male, Female, Adult, Middle Aged, Risk Assessment, Aged, Young Adult, Lung Diseases physiopathology, Lung Diseases epidemiology, Lung Diseases etiology, Lung Diseases diagnosis, Adolescent, Alcohol Drinking adverse effects, Alcohol Drinking epidemiology, Lung physiopathology, Lung drug effects, Respiratory Function Tests
- Abstract
Introduction: The health effects of alcohol are well established but the influence on pulmonary function remains debated. Studies indicate that small amounts of alcohol are beneficial and heavy consumption is harmful, suggesting a U-shaped association. Our objective is to determine whether there is an association between alcohol intake and changes in pulmonary function parameters, exploring the potential protective effect of moderate alcohol consumption and the harm caused by heavy drinking., Methods: A comprehensive search from PubMed, Embase, Cochrane and CINAHL was carried out, and studies were evaluated using the JBI methodological framework for scoping reviews. Two independent reviewers conducted parallel screening and data extraction. A data extraction form was utilised to organise key themes, with qualitative analysis and visual representation of the results., Results: Among 4427 screened abstracts, 179 underwent full-text review, resulting in 30 eligible studies. Of these, 10 showed a negative effect, nine reported no impact, nine exhibited a positive effect and two indicated a nonlinear U-shaped association between alcohol consumption and pulmonary function parameters., Conclusion: While the U-shaped curve hypothesis remains unconfirmed by the current literature, there are notable associations. Heavy alcohol consumption appears to negatively affect pulmonary function, while low to moderate intake shows a positive influence in included studies. However, the diversity in study quality, the nonstandardised alcohol intake quantification and the confounding role of smoking challenge definitive conclusions. The need for consistent, long-term international studies is evident to further explore this relationship while addressing the complex interplay between alcohol and smoking., Competing Interests: Conflict of interest: S.J. Riddersholm reports grants for post-doctoral employment from GE. U.M. Weinreich reports grants from Fisher & Paykel; lecture honoraria from AstraZeneca, GSK, ResMed, Fisher & Paykel, Orion Pharma, Boehringer Ingelheim and Pfizer; payment for expert testimony from GSK; travel support from Chiesi; advisory board participation for AstraZeneca, GSK, Novartis, TEVA and Boehringer Ingelheim; and leadership roles as Chairman of the Danish Respiratory Society, Chairman of the Lungeforeningens Research Grant, outside the submitted work. All other authors have nothing to disclose., (Copyright ©The authors 2024.)
- Published
- 2024
- Full Text
- View/download PDF
24. Pertussis epidemic in Denmark, August 2023 to February 2024.
- Author
-
Nordholm AC, Emborg HD, Nørgaard SK, Nygaard U, Ronayne A, Nielsen LB, Søborg B, Andersen PH, and Dalby T
- Subjects
- Infant, Adolescent, Humans, Female, Pregnancy, Bordetella pertussis, Vaccination, Pregnant People, Incidence, Denmark epidemiology, Pertussis Vaccine, Whooping Cough epidemiology, Whooping Cough prevention & control
- Abstract
We report a record high pertussis epidemic in Denmark since August 2023. Highest incidence was in adolescents, while peak incidence in infants was lower vs previous epidemics in 2019 and 2016. Among infants aged 0-2 months, over half (29/48) were hospitalised and one infant died, underlining the disease severity in the youngest. To protect infants, pertussis vaccination in pregnant women was introduced in January 2024 in the national vaccination programme. Improved vaccination surveillance in pregnant women is being implemented.
- Published
- 2024
- Full Text
- View/download PDF
25. Kidney derived apolipoprotein M and its role in acute kidney injury.
- Author
-
Bisgaard LS, Christensen PM, Oh J, Torta F, Füchtbauer EM, Nielsen LB, and Christoffersen C
- Abstract
Aim: Apolipoprotein M (apoM) is mainly expressed in liver and in proximal tubular epithelial cells in the kidney. In plasma, apoM associates with HDL particles via a retained signal peptide and carries sphingosine-1-phosphate (S1P), a small bioactive lipid. ApoM is undetectable in urine from healthy individuals but lack of megalin receptors in proximal tubuli cells induces loss of apoM into the urine. Besides this, very little is known about kidney-derived apoM. The aim of this study was to address the role of apoM in kidney biology and in acute kidney injury. Methods: A novel kidney-specific human apoM transgenic mouse model (RPTEC-hapoM
TG ) was generated and subjected to either cisplatin or ischemia/reperfusion injury. Further, a stable transfection of HK-2 cells overexpressing human apoM (HK-2-hapoMTG ) was developed to study the pattern of apoM secretion in proximal tubuli cells. Results: Human apoM was present in plasma from RPTEC-hapoMTG mice (mean 0.18 μM), with a significant increase in plasma S1P levels. In vitro apoM was secreted to both the apical (urine) and basolateral (blood) compartment from proximal tubular epithelial cells. However, no differences in kidney injury score was seen between RPTEC-hapoMTG and wild type (WT) mice upon kidney injury. Further, gene expression of inflammatory markers (i.e., IL6, MCP-1) was similar upon ischemia/reperfusion injury. Conclusion: Our study suggests that kidney-derived apoM is secreted to plasma, supporting a role for apoM in sequestering molecules from excretion in urine. However, overexpression of human apoM in the kidney did not protect against acute kidney injury., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 Bisgaard, Christensen, Oh, Torta, Füchtbauer, Nielsen and Christoffersen.)- Published
- 2024
- Full Text
- View/download PDF
26. Correction: Thrombocytopenia and platelet transfusions in ICU patients: an international inception cohort study (PLOT-ICU).
- Author
-
Anthon CT, Pène F, Perner A, Azoulay E, Puxty K, Van De Louw A, Barratt-Due A, Chawla S, Castro P, Póvoa P, Coelho L, Metaxa V, Kochanek M, Liebregts T, Kander T, Hästbacka J, Andreasen JB, Péju E, Nielsen LB, Hvas CL, Dufranc E, Canet E, Lundqvist L, Wright CJ, Schmidt J, Uhel F, Ait-Oufella H, Krag M, Cos Badia E, Díaz-Lagares C, Menat S, Voiriot G, Clausen NE, Lorentzen K, Kvåle R, Hildebrandt T, Holten AR, Strand K, Tzalavras A, Bestle MH, Klepstad P, Fernandez S, Vimpere D, Paulino C, Graça C, Lueck C, Juhl CS, Costa C, Bådstøløkken PM, Miranda T, Lêdo LSA, Sousa Torres JC, Granholm A, Møller MH, and Russell L
- Published
- 2024
- Full Text
- View/download PDF
27. Thrombocytopenia and platelet transfusions in ICU patients: an international inception cohort study (PLOT-ICU).
- Author
-
Anthon CT, Pène F, Perner A, Azoulay E, Puxty K, Van De Louw A, Barratt-Due A, Chawla S, Castro P, Póvoa P, Coelho L, Metaxa V, Kochanek M, Liebregts T, Kander T, Hästbacka J, Andreasen JB, Péju E, Nielsen LB, Hvas CL, Dufranc E, Canet E, Lundqvist L, Wright CJ, Schmidt J, Uhel F, Ait-Oufella H, Krag M, Cos Badia E, Díaz-Lagares C, Menat S, Voiriot G, Clausen NE, Lorentzen K, Kvåle R, Hildebrandt T, Holten AR, Strand K, Tzalavras A, Bestle MH, Klepstad P, Fernandez S, Vimpere D, Paulino C, Graça C, Lueck C, Juhl CS, Costa C, Bådstøløkken PM, Miranda T, Lêdo LSA, Sousa Torres JC, Granholm A, Møller MH, and Russell L
- Subjects
- Adult, Humans, Male, Female, Middle Aged, Cohort Studies, Prospective Studies, Intensive Care Units, Hemorrhage etiology, Retrospective Studies, Platelet Transfusion adverse effects, Thrombocytopenia epidemiology, Thrombocytopenia etiology
- Abstract
Purpose: Thrombocytopenia (platelet count < 150 × 10
9 /L) is common in intensive care unit (ICU) patients and is likely associated with worse outcomes. In this study we present international contemporary data on thrombocytopenia in ICU patients., Methods: We conducted a prospective cohort study in adult ICU patients in 52 ICUs across 10 countries. We assessed frequencies of thrombocytopenia, use of platelet transfusions and clinical outcomes including mortality. We evaluated pre-selected potential risk factors for the development of thrombocytopenia during ICU stay and associations between thrombocytopenia at ICU admission and 90-day mortality using pre-specified logistic regression analyses., Results: We analysed 1166 ICU patients; the median age was 63 years and 39.5% were female. Overall, 43.2% (95% confidence interval (CI) 40.4-46.1) had thrombocytopenia; 23.4% (20-26) had thrombocytopenia at ICU admission, and 19.8% (17.6-22.2) developed thrombocytopenia during their ICU stay. Absence of acquired immune deficiency syndrome (AIDS), non-cancer-related immune deficiency, liver failure, male sex, septic shock, and bleeding at ICU admission were associated with the development of thrombocytopenia during ICU stay. Among patients with thrombocytopenia, 22.6% received platelet transfusion(s), and 64.3% of in-ICU transfusions were prophylactic. Patients with thrombocytopenia had higher occurrences of bleeding and death, fewer days alive without the use of life-support, and fewer days alive and out of hospital. Thrombocytopenia at ICU admission was associated with 90-day mortality (adjusted odds ratio 1.7; 95% CI 1.19-2.42)., Conclusion: Thrombocytopenia occurred in 43% of critically ill patients and was associated with worse outcomes including increased mortality. Platelet transfusions were given to 23% of patients with thrombocytopenia and most were prophylactic., (© 2023. The Author(s).)- Published
- 2023
- Full Text
- View/download PDF
28. The data quality and applicability of a Danish prehospital electronic health record: A mixed-methods study.
- Author
-
Kjær J, Milling L, Wittrock D, Nielsen LB, and Mikkelsen S
- Subjects
- Child, Humans, Retrospective Studies, Data Accuracy, Ambulances, Denmark, Tablets, Electronic Health Records, Emergency Medical Services
- Abstract
Background: Without accurate documentation, it can be difficult to assess the quality of care and the impact of quality improvement initiatives. Prehospital lack of documentation of the basic measurements is associated with a twofold risk of mortality. The aim of this study was to investigate data quality in the electronic prehospital patient record (ePPR) system in the Region of Southern Denmark. In addition, we investigated ambulance professionals' attitudes toward the use of ePPR and identified barriers and facilitators to its use., Method: We used an explanatory sequential mixed-methods design. Phase one consisted of a retrospective assessment of the data quality of ePPR information, and phase two included semi-structured interviews with ambulance professionals combined with observations. We included patients who were acutely transported to an emergency department by ambulance in the Region of Southern Denmark from 2016 to 2020. Data completeness was calculated for each vital sign using a two-way table of frequency. Vital signs were summarised to calculate data correctness. Interviews and observations were analysed using thematic analysis., Results: Overall, an improvement in data completeness and correctness was observed from 2016-2020. When stratified by age group, children (<12 years) accounted for the majority of missing vital sign registrations. In the thematic analysis, we identified four themes; ambulance professionals' attitudes, emergency setting, training and guidelines, and tablet and software., Conclusion: We found high data quality, but there is room for improvement. The ambulance professionals' attitudes toward the ePPR, working in an emergency setting, a notion of insufficient training in completing the ePPR, and challenges related to the tablet and software could be barriers to data completeness and correctness. It would be beneficial to include the end-user when developing an ePPR system and to consider that the tablet should be used in emergency situations., Competing Interests: The authors have declared that no competing interests exist., (Copyright: © 2023 Kjær et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
- Published
- 2023
- Full Text
- View/download PDF
29. eDNA Metabarcoding- and Microscopic Analysis for Diet Determination in Waterfowl, a Comparative Study in Vejlerne, Denmark.
- Author
-
Svendsen AL, Nielsen LB, Schmidt JB, Bruhn D, Andersen LH, and Pertoldi C
- Abstract
Understanding diets and structural food webs are keys to the apprehension of ecological communities, upon which conservation and management biology are based. The understanding of grazing and habitat choice for waterfowl is one of the most important topics for avian ecologists today and can, to some degree, be answered by dietary analysis. Droppings collected from four waterfowl, the Eurasian wigeon ( Anas penelope ), Greylag goose ( Anser anser ), pink-footed goose ( Anser brachyrhynchus ) and Barnacle goose ( Branta leucopsis ) in Vejlerne (Denmark), were analysed microscopically and through eDNA metabarcoding with the use of next generation sequencing (NGS) to accumulate knowledge about the diet of these waterfowl. In total, 120 dropping samples were microscopically analysed, of which the eDNA metabarcoding analysis was done on 79 samples. The prey items were identified according to the taxonomic level of species, and a qualitative method, frequency of occurrence (FO) and FO calculated as a percentage, was used in order to compare the results from the two methods. As neither of the methods was able to encompass all species discovered when combining the two methods, it was concluded in this study that the two methods can support each other in a dietary analysis of waterfowl, but not replace one another.
- Published
- 2023
- Full Text
- View/download PDF
30. LEAP2 is associated with cardiometabolic markers but is unchanged by antidiabetic treatment in people with prediabetes.
- Author
-
Byberg S, Blond MB, Holm S, Amadid H, Nielsen LB, Clemmensen KKB, Færch K, and Holst B
- Subjects
- Humans, Hypoglycemic Agents therapeutic use, Glycated Hemoglobin, Overweight, Blood Glucose metabolism, Obesity complications, Body Weight, Prediabetic State complications, Diabetes Mellitus, Type 2 complications, Insulin Resistance, Metformin therapeutic use, Cardiovascular Diseases epidemiology
- Abstract
To examine whether fasting plasma liver-expressed antimicrobial peptide 2 (FP-LEAP2) is associated with markers of cardiometabolic disease susceptibility in a cohort with prediabetes and overweight/obesity and whether antidiabetic interventions affect FP-LEAP2 levels. The analysis included 115 individuals with prediabetes [hemoglobin A1c (HbA1c) 39-47 mmol/mol, 5.7%-6.4%] and overweight/obesity [body mass index (BMI) ≥ 25 kg/m
2 ] from a randomized controlled trial. Changes in FP-LEAP2 levels were assessed in relation to treatment with dapagliflozin (10 mg once daily), metformin (1,700 mg daily), or interval-based exercise (5 days/wk, 30 min/session) compared with control (habitual lifestyle) after 6 and 13 wk of treatment. FP-LEAP2 levels were positively associated with [standardized beta coefficient (95% CI)]: BMI 0.22 (0.03:0.41), P = 0.027; body weight 0.27 (0.06:0.48), P = 0.013; fat mass 0.2 (0.00:0.4), P = 0.048; lean mass 0.47 (0.13:0.8), P = 0.008; HbA1c 0.35 (0.17:0.53), P < 0.001; fasting plasma glucose (FPG) 0.32 (0.12:0.51), P = 0.001; fasting serum insulin 0.28 (0.09:0.47), P = 0.005; total cholesterol 0.19 (0.01:0.38), P = 0.043; triglycerides 0.31 (0.13:0.5), P < 0.001; and transaminases and fatty liver index (standardized beta coefficients 0.23-0.32), all P < 0.020. FP-LEAP2 levels were inversely associated with insulin sensitivity [-0.22 (-0.41: -0.03), P = 0.022] and kidney function [estimated glomerular filtration rate (eGFR) -0.34 (-0.56: -0.12), P = 0.003]. FP-LEAP2 levels were not associated with fat distribution or body fat percentage, fasting glucagon, postload glucose, β-cell function, or low-density lipoprotein. The interventions were not associated with changes in FP-LEAP2. FP-LEAP2 is associated with body mass, impaired insulin sensitivity, liver-specific enzymes, and kidney function. The findings highlight the importance of studying LEAP2 in obesity, type 2 diabetes, and nonalcoholic fatty liver disease. FP-LEAP2 was not affected by metformin, dapaglifloxin, or exercise in this population. NEW & NOTEWORTHY LEAP2, primarily secreted by the liver, increases with greater body mass, insulin resistance, and liver-specific enzymes in individuals with prediabetes and overweight or obesity. Fasting glucose, body mass, and alanine aminotransferase independently predict LEAP2 levels. LEAP2 is inversely linked to impaired kidney function. Elevated LEAP2 levels might indicate an increased metabolic risk, warranting further investigation into its potential involvement in glucose and body weight control.- Published
- 2023
- Full Text
- View/download PDF
31. Conflicting COVID-19 excess mortality estimates.
- Author
-
Bager P, Nielsen J, Bhatt S, Nielsen LB, Krause TG, and Vestergaard LS
- Subjects
- Humans, Mortality, COVID-19
- Abstract
Competing Interests: We declare no competing interests.
- Published
- 2023
- Full Text
- View/download PDF
32. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease among 948,263 individuals ≥ 65 years of age: a Danish cohort study.
- Author
-
Nielsen KF, Nielsen LB, Lomholt FK, Nørgaard SK, Slotved HC, Dalby T, Fuursted K, Jørgensen CS, and Valentiner-Branth P
- Subjects
- Humans, Cohort Studies, Serogroup, Denmark epidemiology, Pneumococcal Vaccines, Pneumococcal Infections epidemiology, Pneumococcal Infections prevention & control
- Abstract
This study aimed to estimate the effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPV23) against invasive pneumococcal disease (IPD) among individuals ≥ 65 years of age. We used Danish nationwide databases to obtain information on PPV23 vaccination, covariates, and IPD and linked data on an individual level using a unique personal identifier. A total of 948,263 individuals were included and followed between June 15, 2020, and September 18, 2021 (58.6% were vaccinated during follow-up). The adjusted vaccine effectiveness was 42% (95% confidence interval (CI): 9-63%) for all-serotype IPD and 58% (95% CI: 21-78%) for PPV23-serotype IPD, using no vaccination as the reference., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
33. Effects of chemotherapy dose reductions in overweight patients with acute myeloid leukaemia: A Danish nationwide cohort study.
- Author
-
Kristensen DT, Nielsen LB, Jakobsen LHK, Kristensen TC, Jepsen LØ, Schöllkopf C, Theilgaard-Mönch K, El-Galaly TC, Roug AS, and Severinsen MT
- Subjects
- Adult, Humans, Cohort Studies, Drug Tapering, Neoplasm Recurrence, Local drug therapy, Remission Induction, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Denmark epidemiology, Retrospective Studies, Treatment Outcome, Overweight complications, Overweight drug therapy, Leukemia, Myeloid, Acute
- Abstract
Overweight patients with cancer are frequently reduced in chemotherapy dose due to toxicity concerns, although previous studies have indicated that dose reduction (DR) of overweight patients results in comparable toxicity but may compromise overall survival (OS). Current evidence regarding DR in patients with acute myeloid leukaemia (AML) is limited. To investigate the association between DR and outcome among overweight patients with AML we analysed a Danish nationwide cohort of overweight adult AML patients treated with remission induction chemotherapy. Among 536 patients identified, 10.1% were categorized as DR defined as 95% or less of full body surface area (BSA)-based dose. Risk factors for DR were high body mass index (BMI) and BSA, therapy-related AML and favourable cytogenetics. No significant differences were observed for rates of complete remission (CR), 30- and 90-day mortality between DR and non-DR patients. Furthermore, DR did not affect median relapse-free survival (RFS) [DR, 14.5 (95% confidence interval, 9.0-41.7) months; non-DR, 15.0 (12.3-19.3)] with an adjusted difference in five-year restricted mean survival time (Δ5y-RMST) of 0.2 (-8.4 to 8.8) months nor median OS (DR, 17.0 [11.9 to 45.5] months; non-DR, 17.5 [14.8 to 20.5]) with an adjusted Δ5y-RMST of 0.8 (-5.7 to 7.3) months. In conclusion, we found no statistically significant association between DR and outcomes among overweight patients with AML. However, we acknowledge the limited sample size and encourage further studies in this important subject., (© 2022 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.)
- Published
- 2022
- Full Text
- View/download PDF
34. First-Line Treatment of HER2-Positive Metastatic Breast Cancer With Dual Blockade Including Biosimilar Trastuzumab (SB3): Population-Based Real-World Data From the DBCG.
- Author
-
Celik A, Berg T, Nielsen LB, Jensen MB, Ejlertsen B, Knoop A, and Andersson M
- Abstract
Purpose: Dual blockade with trastuzumab and pertuzumab in combination with chemotherapy is the recommended first-line therapy for human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (mBC). The purpose of this retrospective study is to examine the clinical outcomes of the trastuzumab biosimilar SB3 in first-line dual blockade treatment using real-world data of patients with HER-positive mBC., Methods: In Denmark, all women with breast cancer are registered in the database of the Danish Breast Cancer Group (DBCG). From this prospective observational registry, we extracted information on primary diagnosis and treatment of all women with HER2-positive mBC who received first-line treatment with SB3 and pertuzumab from September 1, 2018, to February 29, 2020. Retrospectively collected data from the DBCG database included information concerning treatment start, end, and reason for discontinuation. The primary endpoints for the study were overall survival (OS) and progression-free survival (PFS)., Results: The study included 117 women who received first-line treatment with SB3 and pertuzumab for their HER2-positive mBC. The study population had a mean age of 60 years. A total of 71 patients (61%) had recurrent disease and 46 patients (39%) presented with de novo mBC. The median follow-up was 11.1 and 15.4 months for PFS and OS, respectively. At 12 months, OS was 84% (95% confidence interval [CI], 78-91), whereas the median OS was not reached. The median PFS was 12.7 months (95% CI, 11.1-16.2). Median time on treatment was 8.7 months (95% CI, 7.6-11.4); 36 patients (31%) were still on treatment at end of study., Conclusions: This retrospective real-world, nationwide study demonstrated comparable median PFS to the historical data of using reference trastuzumab and pertuzumab as first-line dual blockade., Competing Interests: Declaration of Conflicting Interests: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: AC reports unrestricted research grant from Danish Cancer Society; AK reports personal fees from Novartis, Roche, AstraZeneca, Daiichi Sankyo, and Pierre Fabre Pharma Norden, outside the submitted work; TB reports institutional grants from Pfizer, Roche, Novartis, AstraZeneca, Oncology Venture, grants from Eisai, and grants from Samsung Bioepis, outside the submitted work; M-BJ reports institutional grants: Samsung Bioepis, NanoString Technologies, and Oncology Venture, outside the submitted work; BE reports institutional grants from NanoString Technologies, AstraZeneca, Novartis, Oncology Venture, Pfizer, Roche, and Samsung Bioepis, outside the submitted work., (© The Author(s) 2022.)
- Published
- 2022
- Full Text
- View/download PDF
35. Increased transmission of SARS-CoV-2 in Denmark during UEFA European championships.
- Author
-
Bennedbæk M, Button MSF, Nielsen LB, Bybjerg-Grauholm J, Wiid Svarrer C, Møller KL, Kristensen B, Legarth R, Gunalan V, Zenas DR, Irshad I, Gubbels S, Sieber RN, Stegger M, Valentiner-Branth P, Rasmussen M, Møller CH, Fonager J, and Moller FT
- Subjects
- Cohort Studies, Denmark epidemiology, Humans, COVID-19 epidemiology, SARS-CoV-2
- Abstract
Denmark hosted four games during the 2020 UEFA European championships (EC2020). After declining positive SARS-CoV-2 test rates in Denmark, a rise occurred during and after the tournament, concomitant with the replacement of the dominant Alpha lineage (B.1.1.7) by the Delta lineage (B.1.617.2), increasing vaccination rates and cessation of several restrictions. A cohort study including 33 227 cases was conducted from 30 May to 25 July 2021, 14 days before and after the EC2020. Included was a nested cohort with event information from big-screen events and matches at the Danish national stadium, Parken (DNSP) in Copenhagen, held from 12 June to 28 June 2021. Information from whole-genome sequencing, contact tracing and Danish registries was collected. Case-case connections were used to establish transmission trees. Cases infected on match days were compared to cases not infected on match days as a reference. The crude incidence rate ratio (IRR) of transmissions was 1.55, corresponding to 584 (1.76%) cases attributable to EC2020 celebrations. The IRR adjusted for covariates was lower (IRR 1.41) but still significant, and also pointed to a reduced number of transmissions from fully vaccinated cases (IRR 0.59). These data support the hypothesis that the EC2020 celebrations contributed to the rise of cases in Denmark in the early summer of 2021.
- Published
- 2022
- Full Text
- View/download PDF
36. The Arg82Cys Polymorphism of the Protein Nepmucin Implies a Role in HDL Metabolism.
- Author
-
Metz S, Krarup NT, Bryrup T, Støy J, Andersson EA, Christoffersen C, Neville MJ, Christiansen MR, Jonsson AE, Witte DR, Kampmann U, Nielsen LB, Jørgensen NR, Karpe F, Grarup N, Pedersen O, Kilpeläinen TO, and Hansen T
- Abstract
Context: Blood lipid levels are linked to the risk of cardiovascular disease and regulated by genetic factors. A low-frequency polymorphism Arg82Cys (rs72836561) in the membrane protein nepmucin, encoded by CD300LG , is associated with lower fasting concentration of high-density lipoprotein cholesterol (HDLc) and higher fasting triglycerides. However, whether the variant is linked to postprandial lipids and glycemic status remains elusive., Objective: Here, we augment the genetic effect of Arg82Cys on fasting plasma concentrations of HDL subclasses, postprandial lipemia after a standardized high-fat meal, and glycemic status to further untangle its role in HDL metabolism., Methods: We elucidated fasting associations with HDL subclasses in a population-based cohort study (Oxford BioBank, OBB), including 4522 healthy men and women. We investigated fasting and postprandial consequences on HDL metabolism in recall-by-genotype (RbG) studies (fasting: 20 carrier/20 noncarrier; postprandial: 7 carrier/17 noncarrier), and shed light on the synergistic interaction with glycemic status., Results: A lower fasting plasma concentration of cholesterol in large HDL particles was found in healthy male carriers of the Cys82 polymorphism compared to noncarriers, both in the OBB ( P = .004) and RbG studies ( P = .005). In addition, the Cys82 polymorphism was associated with low fasting plasma concentrations of ApoA1 ( P = .008) in the OBB cohort. On the contrary, we did not find differences in postprandial lipemia or 2-hour plasma glucose levels., Conclusion: Taken together, our results indicate an association between the Arg82Cys variant and a lower concentration of HDL particles and HDLc, especially in larger HDL subclasses, suggesting a link between nepmucin and HDLc metabolism or maturation., (© The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society.)
- Published
- 2022
- Full Text
- View/download PDF
37. Patients' perspectives on point-of-care diagnostics and treatment by emergency medical technicians in acute COPD exacerbations: A qualitative study.
- Author
-
Christensen HM, Pietersen PI, Laursen CB, Wittrock D, Nadim G, Jørgensen G, Nielsen LB, Sørensen MK, Titlestad IL, Lassen AT, and Mikkelsen S
- Subjects
- Dyspnea, Humans, Point-of-Care Testing, Qualitative Research, Emergency Medical Technicians, Pulmonary Disease, Chronic Obstructive diagnosis, Pulmonary Disease, Chronic Obstructive therapy
- Abstract
Background: In Denmark emergency medical technicians transport patients with acute COPD exacerbations to the nearest emergency department. From a clinical and economic perspective, this transport and assessment at the hospital may be inconvenient if the patient is immediately discharged from the emergency department. We established an emergency technical technicians point-of-care diagnostics and treatment program of patients with COPD with use of ultrasound and blood analysis. Patients' perspectives on treatment at home and sense of security are important to qualify clinical practice at home with patients with acute exacerbation., Aim and Objectives: To explore patient's and relatives' experience of treatment at home during emergency calls due to COPD in exacerbation and to investigate their attitude to avoid hospitalization as well as experience of stress during point-of-care diagnostics in their own home., Method: A qualitative study comprising semi-structured interviews with 16 patients carried out from April 1st, 2019 to March 31st, 2020 in Denmark. Data was analysed inspired by Malteruds' text condensation and informed by Critical Psychology with first person perspective focusing on the patient's views on point-of-care diagnostics and treatment of their COPD in acute exacerbation., Results: The interviews revealed that in order to ensure an experience of quality in the assessment and treatment of patients in their own homes, it was important that the ambulance staff showed great safety and experience in the use of the technical equipment and treatment of dyspnea. It was also of importance that the patients felt confident that their general practitioner followed up on the home treatment initiated., Conclusion: Patients' perspectives showed that point-of-care diagnostics and treatment of acute COPD in exacerbation was considered a qualitative offer by the patients and their relatives. At the same time, it was crucial that the emergency medical technicians showed experience and safety in handling shortness of breath as well as the technical equipment., Trial Registration: Approved by the Danish Data Protection Agency Project-ID: 20/24845., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
38. Patient-reported outcomes in patients with hematological relapse or progressive disease: a longitudinal observational study.
- Author
-
Sommer M, Nielsen LK, Nielsen LB, Brøndum RF, Nielsen MM, Rytter AS, Vesteghem C, Severinsen MT, El-Galaly TC, Bøgsted M, Grønkjær M, and Jørgensen L
- Subjects
- Fatigue, Humans, Patient Reported Outcome Measures, Surveys and Questionnaires, Neoplasm Recurrence, Local, Quality of Life
- Abstract
Background: Patients with hematological cancer who experience relapse or progressive disease often face yet another line of treatment and continued mortality risk that could increase their physical and emotional trauma and worsen their health-related quality of life. Healthcare professionals who use patient-reported outcomes to identify who will have specific sensitivities in particular health-related quality of life domains may be able to individualize and target treatment and supportive care, both features of precision medicine. Here, in a cohort of patients with relapsed or progressive hematological cancer, we sought to identify health-related quality of life domains in which they experienced deterioration after relapse treatment and to investigate health-related quality of life patterns., Method: Patients were recruited in connection with a precision medicine study at the Department of Hematology, Aalborg University Hospital. They completed the European Organization for Research and Treatment of Cancer questionnaire and the Hospital Anxiety and Depression Scale at baseline and at 3, 6, 9, and 12 months after the relapse diagnosis or progressive cancer. Modes of completion were electronically or on paper. Clinically relevant changes from baseline to 12 months were interpreted according to Cocks' guidelines. We quantified the number of patients with moderate or severe symptoms and functional problems and the number who experienced improvements or deterioration from baseline to 12 months., Results: A total of 104 patients were included, of whom 90 (87%) completed baseline questionnaires and 50 (56%) completed the 12-month assessments. The three symptoms that patients most often reported as deteriorating were fatigue (18%), insomnia (18%), and diarrhea (18%). The three functions that patients most often reported as deteriorating were role (16%) and emotional (16%) and cognitive (16%) functioning., Conclusion: In this study, patient-reported outcome data were useful for identifying negatively affected health-related quality of life domains in patients with relapsed or progressive hematological cancer. We identified patients experiencing deterioration in health-related quality of life during treatment and characterized a potential role for patient-reported outcomes in precision medicine to target treatment and supportive care in this patient group., (© 2021. The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
39. Tumour-infiltrating CD4-, CD8- and FOXP3-positive immune cells as predictive markers of mortality in BRCA1- and BRCA2-associated breast cancer.
- Author
-
Jørgensen N, Hviid TVF, Nielsen LB, Sønderstrup IMH, Eriksen JO, Ejlertsen B, Gerdes AM, Kruse TA, Thomassen M, Jensen MB, and Lænkholm AV
- Subjects
- Adult, Breast Neoplasms genetics, Breast Neoplasms metabolism, Breast Neoplasms pathology, CD4 Antigens metabolism, CD8 Antigens metabolism, Denmark, Disease-Free Survival, Female, Forkhead Transcription Factors metabolism, Humans, Middle Aged, Mutation, Prognosis, Young Adult, BRCA1 Protein genetics, BRCA2 Protein genetics, Breast Neoplasms mortality, Lymphocytes, Tumor-Infiltrating immunology
- Abstract
Background: The prognostic value of tumour-infiltrating lymphocytes (TILs) in breast cancer is well-established. However, the investigation of specific T-cell subsets exclusively in BRCA-associated breast cancer is sparse., Methods: Tumour tissues from 414 BRCA-mutated breast cancer patients were analysed by immunohistochemistry and digital image analysis for expression of CD4, CD8 and FOXP3 immune markers. Distribution of CD4-, CD8- and FOXP3-positive cells and clinicopathological characteristics were assessed according to groups of low or high expression. The prognostic value was evaluated as continuous variables in univariate and multivariate analyses of overall survival and disease-free survival., Results: Both CD4 and CD8 expression are associated with histological diagnosis, tumour grade and oestrogen and progesterone receptor expression status. CD4 expression is associated with BRCA gene status. A high percentage of tumour-infiltrating CD4-, CD8- or FOXP3-positive cells is significantly associated with lower mortality in BRCA1- and BRCA2-associated breast cancer and CD8-positive cells are associated with disease-free survival. No heterogeneity according to BRCA gene status was found for the prognostic value of the immune markers., Conclusions: The results support a prognostic role of specific T-cell subsets in BRCA-associated breast cancer and the promising potential of targeting the immune system in the treatment of these patients., (© 2021. The Author(s), under exclusive licence to Springer Nature Limited.)
- Published
- 2021
- Full Text
- View/download PDF
40. Plasma Exosome-Enriched Extracellular Vesicles From Lactating Mothers With Type 1 Diabetes Contain Aberrant Levels of miRNAs During the Postpartum Period.
- Author
-
Frørup C, Mirza AH, Yarani R, Nielsen LB, Mathiesen ER, Damm P, Svare J, Engelbrekt C, Størling J, Johannesen J, Mortensen HB, Pociot F, and Kaur S
- Subjects
- Adult, Biomarkers blood, Exosomes metabolism, Female, Humans, Mothers, Postpartum Period blood, Postpartum Period genetics, Pregnancy, Breast Feeding, Circulating MicroRNA blood, Diabetes Mellitus, Type 1 blood, Diabetes Mellitus, Type 1 genetics, Exosomes genetics
- Abstract
Type 1 diabetes is an immune-driven disease, where the insulin-producing beta cells from the pancreatic islets of Langerhans becomes target of immune-mediated destruction. Several studies have highlighted the implication of circulating and exosomal microRNAs (miRNAs) in type 1 diabetes, underlining its biomarker value and novel therapeutic potential. Recently, we discovered that exosome-enriched extracellular vesicles carry altered levels of both known and novel miRNAs in breast milk from lactating mothers with type 1 diabetes. In this study, we aimed to characterize exosomal miRNAs in the circulation of lactating mothers with and without type 1 diabetes, hypothesizing that differences in type 1 diabetes risk in offspring from these groups are reflected in the circulating miRNA profile. We performed small RNA sequencing on exosome-enriched extracellular vesicles extracted from plasma of 52 lactating mothers around 5 weeks postpartum (26 with type 1 diabetes and 26 age-matched controls), and found a total of 2,289 miRNAs in vesicles from type 1 diabetes and control libraries. Of these, 176 were differentially expressed in plasma from mothers with type 1 diabetes (167 upregulated; 9 downregulated, using a cut-off of abs(log2FC) >1 and FDR adjusted p-value <0.05). Extracellular vesicles were verified by nanoparticle tracking analysis, transmission electron microscopy and immunoblotting. Five candidate miRNAs were selected based on their involvement in diabetes and immune modulation/beta-cell functions: hsa-miR-127-3p, hsa-miR-146a-5p, hsa-miR-26a-5p, hsa-miR-24-3p and hsa-miR-30d-5p. Real-time qPCR validation confirmed that hsa-miR-146a-5p, hsa-miR-26a-5p, hsa-miR-24-3p, and hsa-miR-30d-5p were significantly upregulated in lactating mothers with type 1 diabetes as compared to lactating healthy mothers. To determine possible target genes and affected pathways of the 5 miRNA candidates, computational network-based analyses were carried out with TargetScan, mirTarBase, QIAGEN Ingenuity Pathway Analysis and PantherDB database. The candidates showed significant association with inflammatory response and cytokine and chemokine mediated signaling pathways. With this study, we detect aberrant levels of miRNAs within plasma extracellular vesicles from lactating mothers with type 1 diabetes during the postpartum period, including miRNAs with associations to disease pathogenesis and inflammatory responses., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Frørup, Mirza, Yarani, Nielsen, Mathiesen, Damm, Svare, Engelbrekt, Størling, Johannesen, Mortensen, Pociot and Kaur.)
- Published
- 2021
- Full Text
- View/download PDF
41. The prognostic impact of anthropometrics in acute myeloid leukemia treated with intensive chemotherapy - A Danish nationwide cohort study.
- Author
-
Kristensen D, Nielsen LB, Roug AS, Kristensen TC, Heath A, Jacobsen LH, Nørgaard JM, Jepsen LØ, Schöllkopf C, Theilgaard-Mönch K, and Severinsen MT
- Subjects
- Antineoplastic Combined Chemotherapy Protocols adverse effects, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Denmark epidemiology, Humans, Leukemia, Myeloid, Acute drug therapy, Prognosis, Public Health Surveillance, Treatment Outcome, Body Weights and Measures, Leukemia, Myeloid, Acute epidemiology
- Published
- 2021
- Full Text
- View/download PDF
42. The immune microenvironment and relation to outcome in patients with advanced breast cancer treated with docetaxel with or without gemcitabine.
- Author
-
Stovgaard ES, Asleh K, Riaz N, Leung S, Gao D, Nielsen LB, Lænkholm AV, Balslev E, Jensen MB, Nielsen D, and Nielsen TO
- Subjects
- Deoxycytidine analogs & derivatives, Docetaxel therapeutic use, Female, Humans, Prospective Studies, Retrospective Studies, Tumor Microenvironment, Gemcitabine, Breast Neoplasms drug therapy
- Abstract
Preclinical studies suggest that some effects of conventional chemotherapy, and in particular, gemcitabine, are mediated through enhanced antitumor immune responses. The objective of this study was to use material from a randomized clinical trial to evaluate whether patients with preexisting immune infiltrates responded better to treatment with gemcitabine + docetaxel (GD) compared to docetaxel alone. Formalin fixed, paraffin-embedded breast cancer tissues from SBG0102 phase 3 trial patients randomly assigned to treatment with GD or docetaxel were used. Immunohistochemical staining for CD8, FOXP3, LAG3, PD-1, PD-L1 and CD163 was performed. Tumor infiltrating lymphocytes (TILs) and tumor associated macrophages were evaluated. Prespecified statistical analyses were performed in a formal prospective-retrospective design. Time to progression was primary endpoint and overall survival secondary endpoint. Correlations between biomarker status and endpoints were evaluated using the Kaplan-Meier method and Cox proportional hazards models. Biomarker data was obtained for 237 patients. There was no difference in treatment effect according to biomarker status for the whole cohort. In planned subgroup analysis by PAM50 subtype, in non-luminal (basal-like and HER2E) breast cancers FOXP3 was a significant predictor of treatment effect with GD compared to docetaxel, with a HR of 0.22 (0.09-0.52) for tumors with low FOXP3 compared to HR 0.92 (0.47-1.80) for high FOXP3 TILs (P
interaction = 0.01). Immune biomarkers were not predictive of added benefit of gemcitabine in a cohort of mixed breast cancer subtypes. However, in non-luminal breast cancers, patients with low FOXP3+ TILs may have significant benefit from added gemcitabine., (© 2021 The Author(s). Published with license by Taylor & Francis Group, LLC.)- Published
- 2021
- Full Text
- View/download PDF
43. Prehospital emergency medical technicians can perform ultrasonography and blood analysis in prehospital evaluation of patients with chronic obstructive pulmonary disease: a feasibility study.
- Author
-
Nadim G, Laursen CB, Pietersen PI, Wittrock D, Sørensen MK, Nielsen LB, Rasmussen CH, Christensen HM, Helmerik S, Jørgensen G, Titlestad IL, Lassen AT, and Mikkelsen S
- Subjects
- Feasibility Studies, Hematologic Tests, Humans, Ultrasonography, Emergency Medical Services, Emergency Medical Technicians, Pulmonary Disease, Chronic Obstructive diagnostic imaging, Pulmonary Disease, Chronic Obstructive therapy
- Abstract
Introduction: Crowding of the emergency departments is an increasing problem. Many patients with an exacerbation of chronic obstructive pulmonary disease (COPD) are often treated in the emergency departments for a very short period before discharged to their homes. It is possible that this treatment could take place in the patients' homes with sufficient diagnostics supporting the treatment. In an effort to keep the diagnostics and treatment of some of these patients in their homes and thus to reduce the patient load at the emergency departments, we implemented a prehospital treat-and-release strategy based on ultrasonography and blood testing performed by emergency medical technicians (EMT) or paramedics (PM) in patients with acute exacerbation of COPD., Method: EMTs and PMs were enrolled in a six-hour educational program covering ultrasonography of the lungs and point of care blood tests. During the seasonal peak of COPD exacerbations (October 2018 - May 2019) all patients who were treated by the ambulance crews for respiratory insufficiency were screened in the ambulances. If the patient had uncomplicated COPD not requiring immediate transport to the hospital, ultrasonographic examination of the lungs, measurements of C-reactive protein and venous blood gases analyses were performed. The response to the initial treatment and the results obtained were discussed via telemedical consultation with a prehospital anaesthesiologist who then decided to either release the patient at the scene or to have the patient transported to the hospital. The primary outcome was strategy feasibility., Results: We included 100 EMTs and PMs in the study. During the study period, 771 patients with respiratory insufficiency were screened. Uncomplicated COPD was rare as only 41patients were treated according to the treat-and-release strategy. Twenty of these patients (49%) were released at the scene. In further ten patients, technical problems were encountered hindering release at the scene., Conclusion: In a few selected patients with suspected acute exacerbations of COPD, it was technically and organisationally feasible for EMTs and PMs to perform prehospital POCT-ultrasound and laboratory testing and release the patients following treatment. None of the patients released at the scene requested a secondary ambulance within the first 48 h following the intervention.
- Published
- 2021
- Full Text
- View/download PDF
44. [Læger med en ph.d.-grad - kan vi udnytte kompetencerne endnu bedre?]
- Author
-
Nørrelund H and Nielsen LB
- Subjects
- Denmark, Humans, Coronary Artery Disease, Myocardial Ischemia
- Published
- 2021
45. SKAP2 , a Candidate Gene for Type 1 Diabetes, Regulates β-Cell Apoptosis and Glycemic Control in Newly Diagnosed Patients.
- Author
-
Fløyel T, Meyerovich K, Prause MC, Kaur S, Frørup C, Mortensen HB, Nielsen LB, Pociot F, Cardozo AK, and Størling J
- Subjects
- Adolescent, Animals, Blood Glucose genetics, Child, Child, Preschool, Diabetes Mellitus, Type 1 diagnosis, Diabetes Mellitus, Type 1 genetics, Female, Gene Knockdown Techniques, Genotype, Glycemic Control, Humans, Intracellular Signaling Peptides and Proteins genetics, Islets of Langerhans metabolism, Male, Rats, Apoptosis genetics, Blood Glucose metabolism, Diabetes Mellitus, Type 1 metabolism, Insulin-Secreting Cells metabolism, Intracellular Signaling Peptides and Proteins metabolism, Polymorphism, Single Nucleotide
- Abstract
The single nucleotide polymorphism rs7804356 located in the Src kinase-associated phosphoprotein 2 ( SKAP2 ) gene is associated with type 1 diabetes (T1D), suggesting SKAP2 as a causal candidate gene. The objective of the study was to investigate if SKAP2 has a functional role in the β-cells in relation to T1D. In a cohort of children with newly diagnosed T1D, rs7804356 predicted glycemic control and residual β-cell function during the 1st year after diagnosis. In INS-1E cells and rat and human islets, proinflammatory cytokines reduced the content of SKAP2. Functional studies revealed that knockdown of SKAP2 aggravated cytokine-induced apoptosis in INS-1E cells and primary rat β-cells, suggesting an antiapoptotic function of SKAP2. In support of this, overexpression of SKAP2 afforded protection against cytokine-induced apoptosis, which correlated with reduced nuclear content of S536-phosphorylated nuclear factor-κB (NF-κB) subunit p65, lower nitric oxide production, and diminished CHOP expression indicative of decreased endoplasmic reticulum stress. Knockdown of CHOP partially counteracted the increase in cytokine-induced apoptosis caused by SKAP2 knockdown. In conclusion, our results suggest that SKAP2 controls β-cell sensitivity to cytokines possibly by affecting the NF-κB-inducible nitric oxide synthase-endoplasmic reticulum stress pathway., (© 2020 by the American Diabetes Association.)
- Published
- 2021
- Full Text
- View/download PDF
46. Etiologies and Outcomes of Acute Respiratory Failure in Solid Organ Transplant Recipients: Insight Into the EFRAIM Multicenter Cohort.
- Author
-
Messika J, Darmon M, Mal H, Pickkers P, Soares M, Canet E, Rello J, Bauer PR, van de Louw A, Lemiale V, Taccone FS, Loeches IM, Schellongowski P, Mehta S, Antonelli M, Kouatchet A, Barratt-Due A, Valkonen M, Bruneel F, Pène F, Metaxa V, Moreau AS, Burghi G, Montini L, Barbier F, Nielsen LB, Mokart D, Chevret S, Zafrani L, and Azoulay E
- Subjects
- Aged, Cohort Studies, Female, Humans, Male, Middle Aged, Postoperative Complications mortality, Postoperative Complications therapy, Prospective Studies, Respiratory Insufficiency mortality, Respiratory Insufficiency therapy, Transplant Recipients, Organ Transplantation adverse effects, Postoperative Complications etiology, Respiratory Insufficiency etiology
- Abstract
Background: Respiratory complications of solid organ transplant (SOT) are a diagnostic and therapeutic challenge when requiring intensive care unit (ICU) admission. We aimed at describing this challenge in a prospective cohort of SOT recipients admitted in the ICU., Methods: In this post hoc analysis of an international cohort of immunocompromised patients admitted in the ICU for an acute respiratory failure, we analyzed all SOT recipients and compared their severity, etiologic diagnosis, prognosis, and outcome according to the performance of an invasive diagnostic strategy (encompassing a fiber-optic bronchoscopy and bronchoalveolar lavage), the type of transplanted organ, and the need of invasive ventilation at day 1., Results: Among 1611 patients included in the primary study, 142 were SOT recipients (kidney, n = 73; 51.4%; lung, n = 33; 23.2%; liver, n = 29; 20.4%; heart, n = 7; 4.9%). Lung transplant recipients were younger than other SOT recipients, and severity did not differ across type of received organ. An invasive diagnostic strategy was more frequently performed in lung transplant recipients with a trend toward a higher rate of bacterial etiology in lung than kidney transplant recipients. Overall ICU survival of SOT recipients was 75.4%. Invasive diagnostic strategy, type of transplanted organ, and need of invasive mechanical ventilation at day 1 did not affect ICU prognosis., Conclusions: ICU management of hypoxemic acute respiratory failure in SOT recipients translated into a low ICU mortality rate, whatever the transplanted organ or the acute respiratory failure cause. The post-ICU burden of acute respiratory failure SOT recipients remains to be investigated., (Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
47. Shared care follow-up of patients with B-cell neoplasms based on nurse-led telephone consultations and PRO-data: a feasibility study from the North Denmark Region.
- Author
-
Sommer M, Frandsen L, Jensen P, Nielsen SR, Nielsen LB, Brøndum RF, Bøgsted M, Madsen J, Severinsen MT, Sørensen EE, Grønkjær M, and El-Galaly TC
- Subjects
- B-Lymphocytes, Denmark epidemiology, Feasibility Studies, Follow-Up Studies, Humans, Nurse's Role, Patient Reported Outcome Measures, Surveys and Questionnaires, Telephone, Neoplasms, Referral and Consultation
- Abstract
Background: Patients with B-cell neoplasms in remission are monitored with regular physician visits at the hospital. The current standard follow-up procedure is not evidence-based or individualized to patient needs. To improve and individualize the follow-up, we investigated the feasibility of a shared care follow-up initiative, with alternating physician visits and nurse-led telephone consultations and assessments based on patient-reported outcome (PRO) data., Methods: Patients ≥18 years diagnosed with B-cell neoplasms were eligible for the study when they were in remission and stable without treatment for at least 6 months. Patients were assigned to alternating visits with physicians and nurse-led telephone consultations. The nurse-led telephone consultations were based on PROs, which were collected with the European Organization for Research and Treatment of Cancer questionnaire (EORTC-QLQ-C30), the Myeloproliferative Neoplasm - Symptom Assessment Form, and the Hospital Anxiety and Depression Scale. Patients completed questionnaires before every nurse-led consultation. We also applied the Patient Feedback Form to survey patient acceptance of the requirement of questionnaire completion. We applied descriptive statistics, in terms of counts (n) and proportions (%), to describe the study population and all endpoints., Results: Between February 2017 and December 2018, 80 patients were enrolled. Adherence, measured as the recruitment rate, was 96% (80/83), and the drop-out rate was 6% (5/80). During the study period, 3/80 (4%) patients relapsed, and 5/80 (6%) patients returned to the standard follow-up, because they required closer medical observation. Relapses were diagnosed based on unscheduled visits requested by patients (n = 2) and patient-reported symptoms reviewed by the nurse (n = 1). The response rate to questionnaires was 98% (335/341). A total of 58/79 (74%) patients completed the Patient Feedback Form; 51/57 (89%) patients reported improved communication with health care professionals; and 50/57 (88%) patients reported improved recollection of symptoms as a result of completing questionnaires., Conclusion: Based on patient adherence, a low relapse rate, and positive patient attitudes towards completing questionnaires, we concluded that a shared care follow-up, supported by PROs, was a feasible alternative to the standard follow-up for patients with B-cell disease in remission.
- Published
- 2020
- Full Text
- View/download PDF
48. Acute respiratory failure in immunocompromised patients: outcome and clinical features according to neutropenia status.
- Author
-
Mokart D, Darmon M, Schellongowski P, Pickkers P, Soares M, Rello J, Bauer PR, van de Louw A, Lemiale V, Taccone FS, Martin-Loeches I, Salluh J, Rusinova K, Mehta S, Antonelli M, Kouatchet A, Barratt-Due A, Valkonen M, Landburg PP, Bukan RB, Pène F, Metaxa V, Burghi G, Saillard C, Nielsen LB, Canet E, Bisbal M, and Azoulay E
- Abstract
Background: The impact of neutropenia in critically ill immunocompromised patients admitted in a context of acute respiratory failure (ARF) remains uncertain. The primary objective was to assess the prognostic impact of neutropenia on outcomes of these patients. Secondary objective was to assess etiology of ARF according to neutropenia., Methods: We performed a post hoc analysis of a prospective multicenter multinational study from 23 ICUs belonging to the Nine-I network. Between November 2015 and July 2016, all adult immunocompromised patients with ARF admitted to the ICU were included in the study. Adjusted analyses included: (1) a hierarchical model with center as random effect; (2) propensity score (PS) matched cohort; and (3) adjusted analysis in the matched cohort., Results: Overall, 1481 patients were included in this study of which 165 had neutropenia at ICU admission (11%). ARF etiologies distribution was significantly different between neutropenic and non-neutropenic patients, main etiologies being bacterial pneumonia (48% vs 27% in neutropenic and non-neutropenic patients, respectively). Initial oxygenation strategy was standard supplemental oxygen in 755 patients (51%), high-flow nasal oxygen in 165 (11%), non-invasive ventilation in 202 (14%) and invasive mechanical ventilation in 359 (24%). Before adjustment, hospital mortality was significantly higher in neutropenic patients (54% vs 42%; p = 0.006). After adjustment for confounder and center effect, neutropenia was no longer associated with outcome (OR 1.40, 95% CI 0.93-2.11). Similar results were observed after matching (52% vs 46%, respectively; p = 0.35) and after adjustment in the matched cohort (OR 1.04; 95% CI 0.63-1.72)., Conclusion: Neutropenia at ICU admission is not associated with hospital mortality in this cohort of critically ill immunocompromised patients admitted for ARF. In neutropenic patients, main ARF etiologies are bacterial and fungal infections.
- Published
- 2020
- Full Text
- View/download PDF
49. Using the Danish National Evaluation as a tool to measure patient-perceived drug information.
- Author
-
Nielsen LB, Kruse MG, Hansen CH, Grønkjær LS, and Ejlersen E
- Subjects
- Denmark, Hospitalization, Humans, Patient Discharge, Pharmaceutical Preparations
- Abstract
Introduction: In 2017, as part of the Danish National Evaluation (LUP), some patients at Lillebaelt Hospital reported receiving insufficient information about their drug treatment. The aim of this study was to evaluate the effect of a multifaceted clinical pharmacist intervention on patient-reported levels of drug information received and patients' perceptions of safety and comfortability with their drug treatment., Methods: In this feasibility study, the intervention consisted of a multifaceted service including two patient interviews using a motivational interviewing approach. The interviews were held during admission and after discharge as a follow-up phone call. Patients were asked questions similar to those used in the LUP about the level of information they had received, and they self-evaluated their safety and comfortability with their drug treatment., Results: A total of 157 patients received the intervention; 135 patients were eligible for follow-up. Approximately 60% of the patients responded that the intervention had positively affected their feelings of safety and comfortability with their drug treatment. There was no significant difference in the patients' responses to the LUP questions regarding the level of information they had received before and after the intervention., Conclusions: The intervention improved the majority of the patients' perceptions of safety and comfortability with their drug treatment. Although all patients received information about their drug treatment and their questions were answered, this was not reflected in their responses to the LUP questions., Funding: The Development Council of Lillebaelt Hospital., Trial Registration: The study was approved by the Danish Data Protection Agency., (Articles published in the DMJ are “open access”. This means that the articles are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits any non-commercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.)
- Published
- 2020
50. Apolipoprotein M and Risk of Type 2 Diabetes.
- Author
-
Hajny S, Christoffersen M, Dalila N, Nielsen LB, Tybjærg-Hansen A, and Christoffersen C
- Subjects
- Aged, Cohort Studies, Denmark epidemiology, Diabetes Mellitus, Type 2 epidemiology, Female, Genetic Association Studies, Genetic Predisposition to Disease, Genotype, Humans, Male, Middle Aged, Polymorphism, Single Nucleotide, Prospective Studies, Risk Factors, Apolipoproteins M blood, Apolipoproteins M genetics, Diabetes Mellitus, Type 2 blood, Diabetes Mellitus, Type 2 genetics
- Abstract
Context: Recent studies have discovered a role of apolipoprotein M (apoM) in energy metabolism, and observational analyses in humans suggest an association with type 2 diabetes. The causal relationship remains however elusive., Objective: To investigate whether reduced plasma apoM concentrations are causally linked to increased risk of type 2 diabetes., Design: Prospective study design analyzed by Mendelian randomization., Setting and Participants: Two cohorts reflecting the Danish general population: the Copenhagen City Heart Study (CCHS, n = 8589) and the Copenhagen General Population Study (CGPS; n = 93 857). Observational analyses included a subset of participants from the CCHS with available plasma apoM (n = 725). Genetic analyses included the complete cohorts (n = 102 446). During a median follow-up of 16 years (CCHS) and 8 years (CGPS), 563 and 2132 participants developed type 2 diabetes., Main Outcome Measures: Plasma apoM concentration, genetic variants in APOM, and type 2 diabetes., Results: First, we identified an inverse correlation between plasma apoM and risk of type 2 diabetes in a subset of participants from the CCHS (hazard ratio between highest vs lowest quartile (reference) = 0.32; 95% confidence interval = 0.1-1.01; P for trend = .02). Second, genotyping of specific single nucleotide polymorphisms in APOM further revealed a 10.8% (P = 6.2 × 10-5) reduced plasma apoM concentration in participants with variant rs1266078. Third, a meta-analysis including data from 599 451 individuals showed no association between rs1266078 and risk of type 2 diabetes., Conclusions: The present study does not appear to support a causal association between plasma apoM and risk of type 2 diabetes., (© Endocrine Society 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.